Abstract 232P
Background
Both abiraterone and enzalutamide have shown to improve overall survival (OS), progression-free survival (PFS) and PSA response in patients with metastatic castration-resistant prostate cancer (MCRPC) regardless of previous treatment with chemotherapy (COU-AA301, COU-AA302, AFFIRM and PREVAIL). The data regarding the impact of these treatments in regional health services is scarce. This study assessed the survival outcomes in MCRPC patients in a regional health service in Victoria with the use of abiraterone and enzalutamide.
Methods
This retrospective clinical audit included 75 patients with the diagnosis of MCRPC treated with either abiraterone or enzalutamide between the period of January 1 2014 to December 31 2019 at Goulburn Valley Health. Patients were divided into two groups based on whether they received abiraterone or enzalutamide, and stratified according to ECOG performance, Gleason score, burden of disease, presence of visceral metastases and use of previous chemotherapy. The primary end point was PSA response. The secondary outcomes were PSA PFS, radiographic PFS, and OS.
Results
37 patients received enzalutamide, and the other 38 received abiraterone. Only 20% of patients in either group had visceral metastases. 32% of patients receiving enzalutamide had a high burden of disease, compared to 53% receiving abiraterone. 38% of patients in the enzalutamide group and 53% in the abiraterone group had received prior chemotherapy. PSA response rates were higher in the enzalutamide group than abiraterone group (70.3% vs 37.8%). Both PSA and radiographic PFS were longer in the enzalutamide group than abiraterone group; 7 months vs 5 months for both end points. OS was also found to be longer in patients receiving Enzalutamide; 30 months compared to 13 months in patients receiving Abiraterone.
Conclusions
Both abiraterone and enzalutamide have shown to result in significant PSA response rates, as well as PFS and OS benefit in MCRPC patients in the real-world setting, as reflected in previous clinical trials. The difference in responses and survival benefit between the groups are probably impacted by the unbalanced burden of disease and proportion of prior chemotherapy use.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
7P - Machine learning intratumoral and axillary lymph node magnetic resonance imaging radiomics for predicting axillary lymph node metastasis in patients with early-stage invasive breast cancer (RBC-01 Study)
Presenter: Yujie Tan
Session: e-Poster Display Session
8P - Knowledge, practice and attitudes of physicians in low- and middle-income countries (LMIC) on fertility and pregnancy-related issues in young breast cancer patients
Presenter: Shah Zeb Khan
Session: e-Poster Display Session
9P - Survival status of elderly women with HR+ early breast cancer: An analysis of SEER database
Presenter: Wang Hao
Session: e-Poster Display Session
10P - Neoadjuvant immunotherapy plus chemotherapy in early triple-negative breast cancer: A meta-analysis of randomized controlled trials
Presenter: Jessa Gilda Pandy
Session: e-Poster Display Session
11P - Genetically predicted bipolar disorder is causally associated with increased risk of breast cancer: A Mendelian randomization analysis
Presenter: Haoxin Peng
Session: e-Poster Display Session
12P - Stromal tumour-infiltrating lymphocytes in human epidermal growth factor receptor 2-overexpressing breast cancer: Association with negative nodal metastasis
Presenter: Ren Xiaoqiu
Session: e-Poster Display Session
13P - A retrospective observational study on neoadjuvant chemotherapy in older adults based on the Joint Breast Cancer Registry Singapore
Presenter: Johan Chan
Session: e-Poster Display Session